Form 4: Applied Therapeutics Executive Corwin Dale Hooks Reports Acquisition and Disposal of Shares

Corwin Dale Hooks, Chief Commercial Officer of Applied Therapeutics, Inc., reports the acquisition of 250,000 shares and disposal of 550,000 shares of common stock on March 24, 2025, according to a Form 4 filing with the SEC.

Summary

• On March 24, 2025, Corwin Dale Hooks, the Chief Commercial Officer of Applied Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 250,000 shares of common stock at $0.
• The filing also reports the disposal of 550,000 shares of common stock.
• Following these transactions, Hooks beneficially owns 550,000 shares of Applied Therapeutics, Inc.
• The acquisition of 250,000 shares was through the grant of compensatory Restricted Stock Units (RSUs) under the company's 2019 Equity Incentive Plan.
• One-fourth of the RSUs will vest on March 24, 2026, and the remaining shares will vest monthly thereafter, contingent upon continued service.
• Hooks has granted a Limited Power of Attorney to Les Funtleyder and Catherine Thorpe to handle SEC filings on his behalf.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The acquisition of shares through RSUs is a positive incentive, but the disposal of a larger number of shares could raise concerns. The overall impact is likely to be minimal.

Positives

• The grant of RSUs to a key executive like the Chief Commercial Officer can be seen as a positive incentive for continued service and alignment with company goals.

Negatives

• The disposal of 550,000 shares by the Chief Commercial Officer could be interpreted negatively by the market, although the reason for disposal is not specified in the filing.

Risks

• The vesting of RSUs is contingent upon the Reporting Person continuing to provide services, creating a potential risk if the Reporting Person leaves the company before the RSUs fully vest.
• The disposal of a large number of shares by an executive could create uncertainty among investors.

Future Outlook

The vesting schedule of the RSUs indicates a long-term incentive structure for the Chief Commercial Officer, with vesting occurring over several years contingent on continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future actions.

Comparison to Industry Standards

• Equity compensation in the form of RSUs is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to incentivize and retain key executives.
• Vesting schedules typically range from three to five years, with monthly or quarterly vesting after an initial cliff vesting period, aligning with industry norms.
• Comparable companies such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Sarepta Therapeutics also utilize equity compensation plans for their executives.

Stakeholder Impact

• Shareholders may react to the reported transactions, particularly the disposal of shares, depending on their interpretation of the executive's actions.
• Employees may view the RSU grant as a positive sign of the company's commitment to its executives.

Key Dates

Keywords

Form 4, Applied Therapeutics, Corwin Dale Hooks, Chief Commercial Officer, Beneficial Ownership, Restricted Stock Units, Equity Incentive Plan, SEC Filing, APLT